Navigation Links
Alba Therapeutics Announces Phase IIb Clinical Trial for Oral AT-1001 for the Treatment of Celiac Disease
Date:9/19/2007

BALTIMORE, Sept. 19 /PRNewswire/ -- Alba Therapeutics Corporation today announced that it has dosed its first patient in a six-week Phase IIb trial with oral AT-1001, an inhibitor of gastrointestinal barrier dysfunction, for the maintenance of remission in patients with Celiac Disease (CD). The multi-center, double-blind, placebo-controlled, dose ranging study will evaluate the efficacy, safety and tolerability of AT-1001 in CD subjects during a six-week gluten challenge, while also testing components of a Celiac Disease activity rating index, a new patient-reported outcomes instrument. "This is Alba's fifth human trial with AT-1001 and highlights our efforts to develop paradigms for the treatment of CD and for the assessment of activity in this neglected disease" stated Dr. Blake Paterson, CEO of Alba. "Since there is no effective treatment for CD and no validated means of measuring disease progression, the successful completion of this study will be a tremendous step forward for Celiac patients."

About Celiac Disease

Celiac Disease ("CD") is a T-cell mediated auto-immune disease that occurs in genetically susceptible individuals and is characterized by small intestinal inflammation, injury and intolerance to gluten. According to the National Institutes of Health, CD affects approximately 3 million Americans. The only current treatment for CD is complete elimination of gluten from the diet, which results in remission for some patients.

About AT-1001

AT-1001 is an inhibitor of barrier dysfunction that has been shown to block intestinal permeability and the genesis of some autoimmune diseases, either as a result of reduction of antigen presentation to the body's immune system, or through some unknown inhibitory, direct effect on gastrointestinal associated lymphoid tissue. AT-1001 is orally formulated, has been granted "Fast Track" designation by the U.S. Food and Drug Administration for the treatment of Celiac Disease, and is also bein
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... OAKS, Calif. , July 30, 2015  Amgen (NASDAQ: ... Hassan , partner and managing director of Warburg Pincus LLC, ... are pleased to welcome Fred Hassan and the ... the Amgen Board," said Robert A. Bradway , chairman ... and commitment to innovation will serve Amgen well." ...
(Date:7/30/2015)... CHAGRIN FALLS, Ohio , July 30, 2015 /PRNewswire/ ... in his OMTEC® 2015 keynote address last month that ... business models in order to gain the efficiencies—and develop ... future. Dr. Barsoum,s comments were preceded by ... Tornier, avid entrepreneur and OMTEC moderator, who stressed that ...
(Date:7/30/2015)... , July 30, 2015  Growth of the ... as they bring former prescription users to the OTC ... Kline forecasts robust Rx-to-OTC switch activity over the ... emerging along with many new brands entering the market ... over the next five years (even those with low ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... 2012  Biomerix Corporation announced today that it has received ... tissue repair mesh, a novel composite mesh intended for ... for the temporary bridging of fascial defects.  This approval ... certification in many other parts of the world that ...
... 2012  Sanofi US today announced that the U. S. ... injunction against a Synvisc-One ® (hylan ... ruling allows for a restricted launch of Seikagaku,s product ... prohibits Seikagaku from selling their product below the current ...
Cached Medicine Technology:Biomerix Receives CE Mark Approval For ASSURE Soft Tissue Repair Mesh 2Sanofi Announces Court Ruling Granting Preliminary Injunction Against Synvisc-One® Competitor Product 2
(Date:8/1/2015)... Bronx, NY (PRWEB) , ... August 01, 2015 , ... ... Torah scroll currently housed at their Bronx campus. The goal is to bring this ... once again be used in Jewish rituals and religious services. , Scroll No. ...
(Date:8/1/2015)... ... August 01, 2015 , ... Professional ... portfolio company has acquired Premier Physical Therapy & Wellness (“Premier”) — with 13 ... state-of-the-art clinics. , “Our acquisition of Premier Physical Therapy & Wellness solidifies Professional ...
(Date:8/1/2015)... ... August 01, 2015 , ... BeverlyD, owner and founder of BeverlyD ... hers the very first small business donation to kick off the campaign for healing ... years. Her legacy includes a complete line of raw, organic hair care products, as ...
(Date:7/31/2015)... ... July 31, 2015 , ... That’s right, the ... the STASH awards? The Significant Technological Achievements in Secretive Horticulture (or STASH) Awards, ... as tried-and-true products that have stood the test of time. These include lighting ...
(Date:7/31/2015)... ... August 01, 2015 , ... The Honor Society of Nursing, Sigma Theta ... Future of Nursing (GAPFON) 20-21 July 2015 in San Juan, Puerto Rico. Key nurse ... , Dr. Silvia Cassiani, Advisor, Nursing and Allied Health Personnel Development, Unit of Human ...
Breaking Medicine News(10 mins):Health News:Calvary Hospital Announces Plans to Restore Historic Torah 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 3Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:March4thforWellBeing Foundation Kickoff 2Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4
... to suffer heart attacks, according to a new study. ... Colin Fischbacher at the University of Edinburgh, however, noted that ... to their non-Asian countrymen. ,As part of the ... the 2001 Census to Scottish hospital discharge and mortality data. ...
... Sundahl has announced that he is going around with pop singer ... his romance with Spears began after their meeting at an Alcoholics ... he knew Spears also loved him, and corroborated his claim by ... ,"When I was in the hospital, she sat ...
... princess of Pop music - Britney Spears has openly confessed that ... vow to remain a virgin until she was married. ... said. "It was two years into my relationship with Justin, and ... ,Britney said to a magazine The most painful ...
... and wife of Brad Pitt has commissioned US artist ... celebrate the different stages of her pregnancy. ,Angelina ... request. About the portrait. ,The painting are however ... Angelinas private collection." ,Bachardy is a well-known ...
... blind dates and the web are all pass, for the latest ... flirting. ,This new trend is a blessing for ... going outside for a cigarette. ,This blend of smoking ... in workplaces was introduced, reports The Sun. ,The Irish ...
... Washington University School of Medicine in St. Louis has led ... the upper part of the intestine, raising hopes that ... the future. ,Principal investigator Dr. Nada A. ... Obesity Research at Washington University School of Medicine, first identified ...
Cached Medicine News:Health News:Protein That Absorbs Lipids may Provide Future Weight-loss Strategies 2
... companion product to the new IM3300 EDTV Autoclavable ... Xenon Light Source offers some truly innovative design ... simply to understand and easy to operate. To ... incorporated a new Stand-By Feature, which allows an ...
1000 L, Bulk Recommended for 500 and 1000 L pipettes...
300 L, Bulk Recommended for 250 and 300 L pipettes....
... Robotic Certified Tips for its full line ... with the highest quality, PerkinElmer Robotic Certified ... accuracy in high throughput applications. Tips for ... range from 0.5 L to 235 L. ...
Medicine Products: